Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02044120
Other study ID # ESP1/SARC025
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 2014
Est. completion date January 2021

Study information

Verified date January 2021
Source Sarcoma Alliance for Research through Collaboration
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide and/or irinotecan in patients with pre-treated incurable Ewing sarcoma.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date January 2021
Est. primary completion date January 2021
Accepts healthy volunteers No
Gender All
Age group 13 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed Ewing sarcoma - Evidence of Ewing sarcoma translocation by FISH or RT-PCR. - Must be willing to undergo tumor biopsy at study entry for biologic correlates. - If patient > 18 years, must be willing to undergo on-treatment tumor biopsy unless medically contra-indicated - Recurrent or refractory tumors with no known curative treatment options according to the judgment of the investigator. - Age = 13 years. - Life expectancy of = 3 months. - ECOG performance status 0-2. - Measurable disease on CT or MRI by RECIST 1.1. - Adequate organ function - Patients must have received as a minimum a first line chemotherapy regimen consisting of at least 2 of the following agents: doxorubicin, cyclophosphamide, ifosfamide, etoposide. - Time elapsed from previous therapy must be = 3 weeks for systemic therapy, = 2 weeks for radiation therapy or major surgery. - Patients who have undergone autologous hematopoietic stem cell transplantation are eligible once they have recovered from all toxicities from therapy - Patients who have received allogeneic hematopoietic stem cell transplantation will be eligible 6 months after the procedure provided there is no evidence of active graft-versus-host disease and immunosuppressive treatment has been discontinued for at least 30 days. - Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of central nervous system metastatic disease, have been off glucocorticoids for at least 4 weeks, have no overt evidence of neurological deficit and are = 6 weeks from completion of brain irradiation. - Patients or their legal representative (if the patient is < 18 years old) must be able to read, understand and provide written informed consent to participate in the trial. - Females of childbearing potential as well as males and their partners must agree to use an effective form of contraception during the study and for 6 months following the last dose of study medication. Exclusion Criteria: - Clinically significant unrelated illness which would, in the judgment of the treating physician, compromise the patient's ability to tolerate the investigational agent or be likely to interfere with the study procedures or results. - Patients with baseline QTc > 480 msec. - Inability to swallow capsules. - Known hypersensitivity to any of the components of niraparib or prior hypersensitivity reactions to that class of drugs. - Known hypersensitivity reaction to temozolomide or any of its components, or dacarbazine (DTIC) if enrolled on ARM 1 or irinotecan or any of its components if enrolled on ARM 2 - Concomitant use of any other investigational or anticancer agent(s). - Pregnant patients or patients who are breast feeding. Subjects capable of pregnancy (post menarche and not post-menopausal, defined as over 12 months since final menstrual period) must have a negative pregnancy test within 7 days prior to first dose. - Other clinically significant malignant disease diagnosed within the previous 5 years, excluding intra-epithelial cervical neoplasia or non-melanoma skin cancer. - Active central nervous system disease. - Known history of MDS or AML - Known persistent (> 4 weeks) = Grade 2 neutropenia, = Grade 2 thrombocytopenia or > Grade 3 anemia from prior cancer therapy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
niraparib

Temozolomide

Irinotecan


Locations

Country Name City State
United Kingdom University College London Hospital London
United States University of Michigan Ann Arbor Michigan
United States National Cancer Institute Bethesda Maryland
United States Children's Hospital of Los Angeles Los Angeles California
United States Seattle's Children Cancer Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Sarcoma Alliance for Research through Collaboration

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity and maximum tolerated dose Dose limiting toxicity describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment. The maximum tolerated dose is the highest dose of a drug or treatment that does not cause unacceptable side effects. Approximately 24 months
Secondary Tumor response rate The percentage of patients whose tumor shrinks or disappears after treatment Approximately 24 months
Secondary Progression-free survival The time from starting treatment until disease progression Month 4 and 6
Secondary Duration of response The time from tumor response to disease progression Approximately 24 months
See also
  Status Clinical Trial Phase
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Recruiting NCT06094101 - Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) Phase 1/Phase 2
Recruiting NCT06029218 - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy N/A
Completed NCT00743496 - A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma Phase 1
Recruiting NCT04337177 - Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors Phase 1
Active, not recruiting NCT02945800 - Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma Phase 2
Recruiting NCT06156410 - Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma Phase 1
Recruiting NCT05968768 - To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) Phase 2
Terminated NCT02536183 - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Phase 1
Recruiting NCT03715933 - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Phase 1
Active, not recruiting NCT03220035 - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT05093322 - A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT02856048 - Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer Phase 2/Phase 3
Withdrawn NCT03880123 - Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Phase 1
Completed NCT04956198 - Drug Sensitivity and Mutation Profiling
Recruiting NCT04791228 - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors Phase 2
Recruiting NCT06068075 - Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD N/A
Active, not recruiting NCT03709680 - Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors Phase 1/Phase 2
Recruiting NCT05734066 - Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma Phase 1/Phase 2
Active, not recruiting NCT01807468 - Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors Phase 2